EUVIMEDEUVIMED entdecken
Crossref

Natural history and clinical outcomes in patients with Alzheimer's disease–related psychosis by antipsychotic treatment status in the United States

Sapna Rao iD, Joan Forns, Heather E Danysh, Brian Calingaert, Colleen Dempsey, Thomas Aquilina, Sanjeev Pathak iD, Mary S Anthony, J Bradley Layton

Journal of Alzheimer’s Disease · 2024

DOI: 10.1177/13872877241297361 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Alzheimer’s Disease, 2024. Verfasst von Sapna Rao und 8 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacoepidemiology and Risk Management, RTI Health Solutions, Research Triangle Park, NC, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Antipsychotic Agents, Psychotic Disorders. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: ACADIA Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

While some literature on clinical outcomes in persons with dementia-related psychosis exists, little is known regarding Alzheimer's disease–related psychosis (ADP).

Objective

Describe demographic/clinical characteristics of adults with ADP and estimate incidence of clinical events by antipsychotic treatment status.

Methods

This cohort study identified adults ≥65 years with Alzheimer's disease and incident psychosis (US Medicare database [2013–2018]) and no prior exposure to antipsychotics. Two nonmutually exclusive ADP subcohorts included: patients who initiated treatment with antipsychotic medications (antipsychotic users) and those who remained untreated (antipsychotic nonusers). Baseline characteristics were evaluated before psychosis diagnosis in untreated patients and before antipsychotic initiation in treated patients. Incidence rates were estimated for falls and fractures (composite and separately), seizure/epilepsy (new onset and any), and mortality.

Results

145,333 ADP antipsychotic nonusers and 49,452 antipsychotic users were identified. Both cohorts had similar baseline demographics; however, antipsychotic users versus nonusers had higher baseline skilled nursing facility use (40.3% and 27.8%), mood (72.7% and 62.1%) and anxiety (70.9% and 57.3%) disorders, falls/fractures (39.5% and 33.8%), urinary tract infections (55.1% and 47.0%), and frailty index scores (76.0% and 69.7%). Crude incidence rates (95% confidence interval)/100 person-years in antipsychotic users and nonusers were 70.0 (68.9–71.2) and 55.8 (55.4–56.1) (falls/fractures composite), 69.0 (67.9–70.1) and 54.9 (54.5–55.2) (falls), 38.6 (38.1–39.0) and 33.0 (32.7–33.2) (mortality), and 45.8 (44.9–46.7) and 54.2 (53.9–54.6) (any seizure/epilepsy).

Conclusions

Antipsychotic initiators with ADP had a higher burden of some baseline comorbidities; experienced higher incidence of falls, fractures, and mortality; and had lower incidence of seizure/epilepsy than antipsychotic nonusers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseAntipsychotic AgentsPsychotic DisordersHumansFemaleMaleUnited StatesAgedAged, 80 and overIncidenceCohort StudiesAccidental FallsMedicareTreatment OutcomeFractures, Bone

Stichwörter der Autor:innen

Alzheimer's diseaseepilepsyfallsfracturesmortalityseizures

Substanzen

Antipsychotic Agents

Autor:innen und Institutionen

  • Pharmacoepidemiology and Risk Management, RTI Health Solutions, Research Triangle Park, NC, USA.
  • Pharmacoepidemiology and Risk Management, RTI Health Solutions, Barcelona, Spain.
  • Pharmacoepidemiology and Risk Management, RTI Health Solutions, Waltham, MA, USA.
  • Drug Safety and Pharmacovigilance, ACADIA Pharmaceuticals Inc., Princeton, NJ, USA.
  • Clinical Development, ACADIA Pharmaceuticals Inc., Princeton, NJ, USA.

ORCID-Profile: Sapna Rao, Sanjeev Pathak

Förderung

  • ACADIA Pharmaceuticals

Zitieren

APA

Rao, S., Forns, J., Danysh, H. E., Calingaert, B., Dempsey, C., Aquilina, T., Pathak, S., Anthony, M. S., & Layton, J. B. (2024). Natural history and clinical outcomes in patients with Alzheimer's disease–related psychosis by antipsychotic treatment status in the United States. Journal of Alzheimer’s Disease. https://doi.org/10.1177/13872877241297361

Vancouver

Rao S, Forns J, Danysh HE, Calingaert B, Dempsey C, Aquilina T, et al. Natural history and clinical outcomes in patients with Alzheimer's disease–related psychosis by antipsychotic treatment status in the United States. Journal of Alzheimer’s Disease. 2024. doi:10.1177/13872877241297361

BibTeX
@article{Rao2024,
  author = {Rao, Sapna and Forns, Joan and Danysh, Heather E and Calingaert, Brian and Dempsey, Colleen and Aquilina, Thomas and Pathak, Sanjeev and Anthony, Mary S and Layton, J Bradley},
  title = {Natural history and clinical outcomes in patients with Alzheimer's disease–related psychosis by antipsychotic treatment status in the United States},
  journal = {Journal of Alzheimer’s Disease},
  year = {2024},
  doi = {10.1177/13872877241297361}
}
Kostenlos starten →